MAO-A inhibitors are used mainly as antidepressants, while selective MAO-B inhibitors are used mainly in Parkinson’s disease. The distinction is not absolute: selectivity depends on the medicine, formulation, and dose, and a drug that is selective for MAO-B at its usual dose can lose that selectivity at higher doses. Both groups can interact dangerously with antidepressants, some opioids, stimulants, decongestants, and tyramine-containing foods, so treatment and any switch require a complete medication review and a prescriber-supervised washout.
What MAO-A and MAO-B inhibitors do
Monoamine oxidase (MAO) is an enzyme that breaks down several chemical messengers in the nervous system and other tissues. Medicines called MAO inhibitors (MAOIs) block one or both forms of the enzyme, allowing more of those messengers to remain available.
As an Amazon Associate I earn from qualifying purchases.
MAO-A preferentially metabolizes serotonin and norepinephrine and also contributes to dopamine metabolism. Blocking it can increase signaling involved in mood, anxiety, attention, and autonomic function. MAO-B has a larger role in dopamine breakdown in the brain. Blocking MAO-B can prolong dopamine activity, which is why selective MAO-B inhibitors are used in Parkinson’s disease.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchThe practical summary used in UK medicines education is: “MAO-B inhibitors (eg rasagiline and selegiline) are used in the treatment of Parkinson’s disease whereas MAO-A inhibitors are used as antidepressants.” That is a description of usual clinical roles, not a guarantee that every product has the same indication in every country.
#1 Best Overall
MAO-A vs MAO-B at a glance
| Feature | MAO-A-focused treatment | MAO-B-focused treatment |
|---|---|---|
| Primary clinical role | Antidepressant treatment, usually when other options have not worked or are unsuitable | Parkinson’s disease, alone in some early cases or as an add-on to levodopa or a dopamine agonist |
| Representative medicines | Phenelzine, tranylcypromine, and isocarboxazid (oral, non-selective MAOIs) | Rasagiline and oral selegiline; the exact approved products and indications vary by country |
| Enzyme action | Strong inhibition of MAO-A; classic oral medicines also inhibit MAO-B at therapeutic doses | Preferential inhibition of MAO-B at recommended doses |
| Main neurotransmitter effect | Raises serotonin and norepinephrine, with effects on dopamine as well | Reduces dopamine breakdown; effects on serotonin and norepinephrine are less central at selective doses |
| Food concern | Many labels require avoidance of aged or fermented, tyramine-rich foods and careful dietary counseling | Routine restriction may not be required at recommended rasagiline doses, but very high tyramine exposure can still cause severe hypertension; follow the product leaflet |
| High-risk medicines | Other antidepressants, central-nervous-system stimulants or depressants, certain opioids, and sympathomimetic cold medicines | The same interaction categories remain relevant, especially serotonergic antidepressants, certain opioids, and other MAOIs |
| Typical monitoring emphasis | Mood response, blood pressure, orthostatic symptoms, pulse, and interaction or dietary risks | Parkinson’s motor symptoms, blood pressure, nausea and other adverse effects, dyskinesia when combined with dopaminergic therapy, and interaction screening |
Neither column should be read as “safe” versus “unsafe.” A non-selective MAO-A medicine generally has broader interaction and dietary restrictions, but a selective MAO-B product can become less selective as the dose rises and can still participate in life-threatening interactions.
Which medicines are considered MAO-A inhibitors?
Classic oral antidepressant MAOIs
Phenelzine, tranylcypromine, and isocarboxazid are established oral MAOI antidepressants listed in US Food and Drug Administration (FDA) safety information. They inhibit MAO-A and MAO-B rather than remaining narrowly selective for one isoenzyme. They may be considered for severe or treatment-resistant depression, but their use requires a clinician who can review the patient’s full medicine list, medical history, blood pressure, and ability to follow interaction precautions.
These medicines are not interchangeable with selective MAO-B treatment for Parkinson’s disease. Their broader enzyme inhibition changes the interaction profile, and the antidepressant indication usually calls for a different risk–benefit assessment than dopamine-focused treatment.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Selegiline transdermal treatment is a different formulation
Selegiline illustrates why the product and route matter. Oral selegiline is used as a selective MAO-B inhibitor in Parkinson’s disease at its approved doses. Selegiline delivered through a transdermal patch is listed by the FDA among MAOI medicines for depression. The same active molecule does not make the two formulations automatically interchangeable: dose, absorption, selectivity, food instructions, and washout requirements can differ. Use the instructions for the exact product prescribed.
What to expect from MAO-A inhibition
By increasing serotonin and norepinephrine, MAO-A-focused treatment can affect mood and anxiety, but it can also alter blood pressure, pulse, sleep, and gastrointestinal function. FDA consumer information warns against combining MAOIs with other depression medicines or with central-nervous-system stimulants or depressants unless a specialist has explicitly planned the combination. Reported serious reactions include marked blood-pressure changes, palpitations, fainting, and stroke.
Which MAO-B inhibitors are used for Parkinson’s disease?
Rasagiline and selegiline
The NHS identifies rasagiline and selegiline as MAO-B inhibitors for Parkinson’s disease. They may be prescribed alone in early disease or added to levodopa or a dopamine agonist when symptoms or “wearing-off” fluctuations need additional control.
Their average symptomatic benefit is modest compared with levodopa. The NHS states that both medicines can improve Parkinson’s symptoms, “although their effects are small compared with levodopa.” A clinician may still choose one because it can smooth treatment, delay or reduce some levodopa adjustments, or fit a person’s other medicines and side-effect pattern.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesAdjunct treatment and motor fluctuations
NICE lists an MAO-B inhibitor as an adjunct option for motor fluctuations. The recommendation is about symptom control, not disease modification. NICE specifically advises against using MAO-B inhibitors as neuroprotective therapy outside clinical trials. A person should therefore not start, continue, or increase one with the expectation that it will slow the underlying progression of Parkinson’s disease.
Common adverse effects
NHS information lists nausea, headache, abdominal pain, and either high or low blood pressure among possible effects. When an MAO-B inhibitor is added to levodopa or another dopaminergic medicine, the prescriber also watches for excessive dopaminergic effects, including troublesome involuntary movements or a need to adjust the companion medicine. New fainting, severe headache, chest symptoms, or a major change in blood pressure warrants urgent medical advice.
How selective is an MAO-B inhibitor?
Selectivity is dose- and formulation-dependent. Rasagiline labeling describes the medicine as selective for MAO-B at recommended doses but notes that selectivity diminishes as the dose rises. This is why “MAO-B inhibitor” does not mean “free of MAO-A-type interactions.” A dose increase, an unapproved dosing pattern, or a different formulation can produce a broader pharmacologic effect.
At selective doses, MAO-B treatment is usually less likely than a non-selective oral MAOI to create a classic tyramine reaction, but the risk is not zero. The rasagiline label discusses very high-tyramine foods—more than 150 mg in the cited labeling discussion—as capable of producing severe hypertension even at recommended doses. That figure is not a universal daily food limit: tyramine content varies widely, and instructions differ by country and formulation.
Interactions that require a medication review
Serotonin syndrome
Combining MAO inhibition with another serotonergic drug can cause serotonin syndrome, a potentially fatal emergency. The MHRA describes it as a medical emergency. Symptoms can include agitation or confusion, sweating, fever, tremor, diarrhea, muscle rigidity, loss of coordination, or rapidly changing blood pressure and pulse. Severe symptoms, collapse, seizure, or a high temperature require emergency services.
DailyMed’s rasagiline labeling reports serotonin-syndrome risk with selective serotonin-reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic and tetracyclic antidepressants, trazodone-like agents, and other MAO inhibitors. The label also identifies the opioids meperidine, tramadol, methadone, and propoxyphene as interaction concerns. Do not assume that a low antidepressant dose or a “Parkinson’s dose” removes the need for screening.
Other MAO inhibitors and antidepressants
Taking two MAO-inhibiting products can produce excessive monoamine activity and dangerous blood-pressure or neurologic reactions. This includes switching between an antidepressant MAOI and an MAO-B product, switching between different antidepressant classes, or using a patch and an oral product without a planned transition. A prescriber or pharmacist must identify every current and recently stopped medicine before the new one is started.
Stimulants, depressants, and decongestants
FDA consumer guidance warns against MAOIs with central-nervous-system stimulants or depressants. Cold and allergy products can also be a problem: sympathomimetic decongestants may raise blood pressure and heart rate when combined with MAO inhibition. Check combination products, not just the ingredient you intended to buy, and ask a pharmacist before using an over-the-counter product, pre-workout stimulant, or recreational substance.
Blood-pressure emergencies
Excess monoamine activity can produce a sudden, severe rise in blood pressure, often with intense headache, palpitations, chest discomfort, shortness of breath, visual changes, or neurologic symptoms. A sudden severe headache, weakness on one side, trouble speaking, fainting, or chest pain is an emergency; call local emergency services rather than waiting for the next appointment.
Food and tyramine: what to avoid and what not to assume
Why tyramine matters
Tyramine is produced as some protein-rich foods age or ferment. When MAO-A is broadly inhibited, tyramine can enter the circulation in larger amounts and trigger a release of stored norepinephrine, causing a dangerous blood-pressure surge. Classic oral MAOIs therefore come with explicit dietary counseling about aged, fermented, or otherwise high-tyramine foods.
Examples covered by many MAOI leaflets
- Aged cheeses and strongly aged dairy products
- Cured, fermented, or improperly stored meats and fish
- Some fermented soy products, yeast extracts, and alcoholic beverages
- Any food specifically listed in the leaflet for the exact product
Recipes, storage time, serving size, and manufacturing methods change tyramine levels, so a generic internet list cannot replace the medicine’s own dietary instructions.
Rasagiline and dietary restrictions
At recommended rasagiline doses, routine dietary restriction is generally not required according to the cited labeling discussion. The same labeling warns that very high-tyramine foods—above 150 mg in that discussion—may still cause severe hypertension. This is a warning about unusual, very large exposures, not permission to ignore symptoms or the local leaflet. If your country’s product information gives a stricter list, follow that version.
How doctors decide between an MAO-A and an MAO-B inhibitor
| Clinical question | How it influences the choice |
|---|---|
| Is the target condition depression or Parkinson’s disease? | Antidepressant MAOIs are MAO-A-focused or non-selective; rasagiline and oral selegiline are used for Parkinson’s symptoms. |
| What medicines are being taken now or were stopped recently? | Recent antidepressants, opioids, stimulants, decongestants, and other MAOIs may require a planned washout or a different treatment. |
| Is blood pressure stable? | Supine hypertension, orthostatic hypotension, fainting, or cardiovascular disease can change the risk–benefit assessment and monitoring plan. |
| Can the person follow food and medicine precautions? | Broad MAOI therapy may require detailed dietary restrictions and avoidance of many over-the-counter products. |
| Is Parkinson’s treatment already causing dyskinesia or other dopaminergic effects? | An add-on MAO-B inhibitor may require adjustment of levodopa or a dopamine agonist rather than simply adding another dose. |
| What does the local product label allow? | Approved indications, formulation instructions, food warnings, and interaction language differ by country. |
The choice is therefore not a contest in which one enzyme target is always safer. It is a supervised decision based on the indication, other medicines, cardiovascular and psychiatric history, dose, formulation, and the person’s ability to follow precautions.
Best Value
Switching antidepressants or Parkinson’s medicines: why washout timing matters
There is no single washout interval that applies to every switch. The necessary gap depends on the medicine being stopped, its half-life and active metabolites, the formulation, the intended new medicine, dose, liver and kidney function, and the interaction being avoided. Some products remain pharmacologically active after the last tablet or patch is removed.
Do not stop an antidepressant abruptly, start an MAOI early, or restart a recently stopped medicine without the prescriber’s written plan. The prescriber or pharmacist may need to:
- List every prescription, over-the-counter medicine, supplement, patch, and recreational drug used recently.
- Identify serotonergic, opioid, sympathomimetic, stimulant, and other MAO-inhibiting products.
- Check the product information for the required interval for that exact formulation and country.
- Plan monitoring for withdrawal, return of depression or Parkinson’s symptoms, blood pressure changes, and serotonin-toxicity symptoms during the transition.
- Give a clear start date and emergency instructions; do not improvise if a dose is missed or the switch is delayed.
If a new prescriber is involved, provide the old prescription, the date and time of the last dose, and any written taper or washout instructions. When the timing is uncertain, a pharmacist can often verify the interaction plan before the next dose.
Safety checklist before starting or renewing treatment
- Bring an up-to-date list of all medicines, including cold remedies, pain medicines, sleep aids, supplements, and herbal products.
- Tell the clinician about fainting, uncontrolled blood pressure, heart disease, severe headaches, seizures, liver disease, pregnancy, and previous medication reactions.
- Confirm whether the prescription is oral, transdermal, immediate-release, or another formulation; instructions are not automatically transferable.
- Ask which foods are restricted for that exact product and whether the advice changes at the prescribed dose.
- Use one pharmacy when possible so interaction software can detect medicines prescribed by different clinicians.
- Read the patient leaflet each time the product or dose changes; country-specific warnings can differ.
- Seek urgent help for severe headache, chest pain, fainting, high fever, marked agitation or confusion, muscle rigidity, seizure, or stroke-like symptoms.
Bottom line for patients and caregivers
MAO-A inhibitors are principally antidepressants, while selective MAO-B inhibitors such as rasagiline and oral selegiline are principally Parkinson’s medicines. MAO-B selectivity lowers—but does not eliminate—interaction concerns, and selectivity can diminish at higher doses. The safest approach is to treat every MAOI prescription as an interaction-sensitive medicine: verify the exact formulation, review all current and recently stopped drugs, follow the product’s food instructions, and use a clinician-supervised washout for any switch.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
